On February 15, 2021 NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), reported the enrollment and first week of treatment of the first patient in the third, high dose cohort of the Phase 1/2 clinical trial (Press release, NOXXON, FEB 15, 2021, View Source [SID1234575075]). The study investigates three dose regimens of NOX-A12 (200, 400 and 600 mg/week), each combined with external-beam radiotherapy in newly diagnosed brain cancer patients who would not benefit clinically from treatment with standard chemotherapy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Once the newly enrolled patient in the third cohort has received a four-week treatment of NOX-A12 and radiotherapy, the Data Safety Monitoring Board will convene to determine whether it is safe to recruit the remaining two patients into the cohort.
"As we enter the last cohort of the dose escalation trial and obtain sufficient data, we will soon be in a position to determine the recommended dose for our next randomized, controlled brain cancer trial which will compare NOX-A12 combined with radiotherapy to standard of care. We then plan to recruit additional patients to broaden the safety and efficacy data-set. The additional data will provide a comprehensive basis for discussions with EU and US regulators concerning plans for our next trial, which is planned to be registrational," commented Aram Mangasarian, CEO of NOXXON. "Recruitment into the current trial continues in our six study centers, three of which were added in October 2020 in order to mitigate the challenges faced by hospital staff as a result of the COVID-19 pandemic. Six months of data from the second and third cohorts of patients should be available at end-Q2 2021 and end-Q3 2021, respectively," he concluded.